Skip to Main Content
Services Talent Knowledge
Site Search
Menu

PressRelease

October 14, 2009

The Legal Project Honors Hiscock & Barclay

Hiscock & Barclay will receive the Barry Gold Law Firm Leadership Award from The Legal Project at its 14th Annual Pro Bono Reception on October 22nd at the New York State Museum in Albany, NY. The event recognizes the years of service of the Legal Project and the attorneys from the Capital District who volunteer their time to provide free civil legal services to the working poor, who often appear "on paper" to not be eligible for assigned counsel, but who cannot afford to pay for legal representation, including victims of domestic violence. Hiscock & Barclay attorney Senator Neil Breslin will also receive the Legal Project Champion Award.

According to The Legal Project Executive Director Lisa Frisch, "We have chosen to recognize Hiscock & Barclay for its leadership in developing its comprehensive pro bono policy, for working to develop an effective pro bono referral plan for the variety of cases that The Legal Project provides services, and for the support that the Firm has provided to individual attorneys at the Firm who have gone above and beyond in their pro bono efforts, such as Jessica Norgrove, winner of the 2008 Brigid Nolan Award."

For more information on this event, contact The Legal Project at (518) 435-1770.

Subscribe

Click here to sign up for alerts, blog posts, and firm news.

Featured Media

Alerts

Massachusetts Federal Court Permits Sharing Clause in Protective Order in Products Liability Case

Alerts

NYS Court of Appeals Holds That Parent May Not Recover for Emotional Injuries in Prenatal-Injury Case

Alerts

Smarter Inventory Management for Pharmacies: Navigating Online Marketplace Compliance

Alerts

Emergency Wine Run, Now Legal: New York State Opens Retail-to-Retail Sales

Alerts

California's Updated Privacy Regulations: Automated Decisionmaking Technology, Cybersecurity Audits, and Risk Assessments, Part 1

Alerts

Pharmacies on High Alert: Optum Rx's 25-Percent Therapeutic-Class Cap Creates Major Legal, Operational, and Competitive Risks